239 related articles for article (PubMed ID: 1383635)
21. Effect of pituitary adenylate cyclase activating polypeptide 1-27 on ocular, cerebral and skin blood flow in humans.
Dorner GT; Wolzt M; Eichler HG; Schmetterer L
Naunyn Schmiedebergs Arch Pharmacol; 1998 Dec; 358(6):657-62. PubMed ID: 9879725
[TBL] [Abstract][Full Text] [Related]
22. Aging-Induced Modulation of Pituitary Adenylate Cyclase-Activating Peptide- and Vasoactive Intestinal Peptide-Induced Vasomotor Responses in the Arteries of Mice.
Ivic I; Solymar M; Fulop BD; Hashimoto H; Toth G; Tamas A; Juhasz T; Koller A; Reglodi D
J Vasc Res; 2017; 54(6):359-366. PubMed ID: 29131060
[TBL] [Abstract][Full Text] [Related]
23. Effects of intravenously infused pituitary adenylate cyclase-activating polypeptide on adenohypophyseal Hormone secretion in normal men.
Chiodera P; Volpi R; Capretti L; Caffarri G; Magotti MG; Coiro V
Neuroendocrinology; 1996 Sep; 64(3):242-6. PubMed ID: 8875442
[TBL] [Abstract][Full Text] [Related]
24. PACAP-27 and PACAP-38: vascular effects in the eye and some other tissues in the rabbit.
Nilsson SF
Eur J Pharmacol; 1994 Feb; 253(1-2):17-25. PubMed ID: 7912197
[TBL] [Abstract][Full Text] [Related]
25. Vasoactive properties of calcitonin gene-related peptide in human skin.
Dias M; Newton D; McLeod G; Belch JJ; Khan F
Int Angiol; 2011 Oct; 30(5):424-8. PubMed ID: 21804480
[TBL] [Abstract][Full Text] [Related]
26. The effects of pituitary adenylate cyclase-activating polypeptide on cerebral arteries and vertebral artery blood flow in anesthetized dogs.
Seki Y; Suzuki Y; Baskaya MK; Kano T; Saito K; Takayasu M; Shibuya M; Sugita K
Eur J Pharmacol; 1995 Mar; 275(3):259-66. PubMed ID: 7768293
[TBL] [Abstract][Full Text] [Related]
27. Effects of pituitary adenylate cyclase-activating polypeptide (PACAP) and vasoactive intestinal polypeptide (VIP) on prolactin, luteinizing hormone and growth hormone secretion in the ewe.
Sawangjaroen K; Curlewis JD
J Neuroendocrinol; 1994 Oct; 6(5):549-55. PubMed ID: 7827625
[TBL] [Abstract][Full Text] [Related]
28. Pituitary adenylate cyclase activating polypeptide (PACAP) is localized in human dermal neurons and causes histamine release from skin mast cells.
Odum L; Petersen LJ; Skov PS; Ebskov LB
Inflamm Res; 1998 Dec; 47(12):488-92. PubMed ID: 9892043
[TBL] [Abstract][Full Text] [Related]
29. Comparison of the vasodilatory effects of vasoactive intestinal polypeptide (VIP) and peptide-HI (PHI) in the rabbit and the cat.
Nilsson SF; Mäepea O
Acta Physiol Scand; 1987 Jan; 129(1):17-26. PubMed ID: 3565040
[TBL] [Abstract][Full Text] [Related]
30. Vasodilatation by calcitonin gene-related peptide and by substance P: a comparison of their effects on resistance and capacitance vessels of human forearms.
McEwan JR; Benjamin N; Larkin S; Fuller RW; Dollery CT; MacIntyre I
Circulation; 1988 May; 77(5):1072-80. PubMed ID: 2452035
[TBL] [Abstract][Full Text] [Related]
31. Differential effects of PACAP and VIP on the pulmonary and hindquarters vascular beds of the cat.
Minkes RK; McMahon TJ; Hood JS; Murphy WA; Coy DH; McNamara DB; Kadowitz PJ
J Appl Physiol (1985); 1992 Mar; 72(3):1212-7. PubMed ID: 1568976
[TBL] [Abstract][Full Text] [Related]
32. Analysis of responses to pituitary adenylate cyclase activating polypeptide-38 in the feline hindquarters vascular bed.
Santiago JA; Kadowitz PJ
Eur J Pharmacol; 1993 Oct; 243(3):291-4. PubMed ID: 7903943
[TBL] [Abstract][Full Text] [Related]
33. VIP/PACAP receptor mediation of cutaneous active vasodilation during heat stress in humans.
Kellogg DL; Zhao JL; Wu Y; Johnson JM
J Appl Physiol (1985); 2010 Jul; 109(1):95-100. PubMed ID: 20395540
[TBL] [Abstract][Full Text] [Related]
34. Evidence for a possible synergism between pituitary adenylate cyclase activating polypeptide and calcitonin gene-related peptide in porcine ophthalmic artery.
Elsås T; White LR
Acta Ophthalmol Scand; 1997 Apr; 75(2):159-61. PubMed ID: 9197563
[TBL] [Abstract][Full Text] [Related]
35. The differential effect of VIP and PACAP on guinea pig gallbladder in vitro.
Greaves RR; O'Donnell LJ; Battistini B; Forget MA; Farthing MJ
Eur J Gastroenterol Hepatol; 2000 Nov; 12(11):1181-4. PubMed ID: 11111773
[TBL] [Abstract][Full Text] [Related]
36. Central pituitary adenylate cyclase-activating polypeptide (PACAP) and vasoactive intestinal peptide (VIP) decrease the baroreflex sensitivity in trout.
Lancien F; Mimassi N; Conlon JM; Le Mével JC
Gen Comp Endocrinol; 2011 Apr; 171(2):245-51. PubMed ID: 21320504
[TBL] [Abstract][Full Text] [Related]
37. Effects of pituitary adenylate cyclase activating polypeptide (PACAP) and vasoactive intestinal polypeptide (VIP) on the cardiovascular system in sheep.
Sawangjaroen K; Dallemagne CR; Cross RB; Curlewis JD
Peptides; 1992; 13(5):1029-32. PubMed ID: 1480509
[TBL] [Abstract][Full Text] [Related]
38. The effect of VIP/PACAP family of peptides on pancreatic blood flow and secretion in conscious dogs.
Ito O; Naruse S; Kitagawa M; Ishiguro H; Ko S; Nakajima M; Hayakawa T
Regul Pept; 1998 Nov; 78(1-3):105-12. PubMed ID: 9879753
[TBL] [Abstract][Full Text] [Related]
39. PACAP-induced plasma extravasation in rat skin.
Cardell LO; Stjärne P; Wagstaff SJ; Agustí C; Nadel JA
Regul Pept; 1997 Aug; 71(2):67-71. PubMed ID: 9416988
[TBL] [Abstract][Full Text] [Related]
40. Comparison of responses to pituitary adenylate cyclase activating peptides 38 and 27 in the pulmonary vascular bed of the cat.
Cheng DY; McMahon TJ; Dewitt BJ; Carroll GC; Lee SS; Murphy WA; Bitar KG; Coy DH; Kadowitz PJ
Eur J Pharmacol; 1993 Oct; 243(1):79-82. PubMed ID: 7902814
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
